Arunjyoti Bio (530881)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with what I know. Arunjyoti Bio trades at ₹65, giving it a market cap of ₹122 crore. Yet the latest quarter shows sales of ₹6 crore and net profit of ₹0 crore. Over the full year, return on equity is -1.90% and return on capital employed is only 4.03%. So on an earnings basis, I cannot pay any amount of genuine value; the P/E is effectively zero because there is no earning power. The balance sheet is even more troubling. Book value is ₹1.96 per share, so I am being asked to pay 33 times book for a business that destroys shareholder value. This is not an investment; it is a hope. Sales growth of 5.20% is unexciting, and the reported 105.62% profit growth is off a base so low that it still produces no actual profit. There is no dividend to compensate, and promoter holding is not disclosed—a basic transparency box that should never be left blank. Ben Graham would insist on a margin of safety. Here the 52-week range of ₹5.05 to ₹65.00 tells me the market has already priced in a story, not a business. The Piotroski F-Score of 7/9 suggests some operational improvements, but a score cannot justify a 33-fold price-to-book premium when returns are negative. The industry label 'Other Financial Services' is vague; I need to know how ₹6 crore of quarterly sales becomes zero profit. If this were a durable franchise, I would see high returns on capital and pricing power. Instead I see none. I cannot value it on fundamentals, so I would not own it. The rational move is to keep my capital and wait for a price that offers a margin of safety.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer